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Apoptosis, a form of programmed cell death, is a highly regulated process, the
deregulation of which has been associated with the tumor initiation, progression, and
metastasis in various cancers including breast cancer. Induction of apoptosis is a popular
target of various therapies currently being tested or used for breast cancer treatment.
Thus, identifying apoptotic mediators and regulators is imperative for molecular biologists
and clinicians for benefit of patients. The regulation of apoptosis is complex and involves
a tight equilibrium between the pro- and anti-apoptotic factors. Recent studies have
highlighted the role of miRNAs in the control of apoptosis and their interplay with p53,
the master guardian of apoptosis. Here, we summarize and integrate the data on the role
of miRNAs in apoptosis in breast cancer and the clinical advantage it may offer for the
prognosis or treatment of breast cancer patients.
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INTRODUCTION
Breast cancer is the most common malignancy in women in western nations with a scary current
estimate of one in eight US women likely to develop invasive breast cancer once in her lifetime
(American Cancer Society, 2015; Ferlay et al., 2015). The lowest incidences of breast cancer are
seen in Asia and Africa but the cases are steadily rising and poor survival rates remain a cause of
grave concern (American Cancer Society, 2015; Ferlay et al., 2015). The various risk factors are
age, density of the breast, family and personal health history, germline mutations in the tumor
suppressor genes-BRCA1, BRCA2, and other breast cancer susceptibility genes, alcohol intake,
endogenous estrogen levels, use of hormone replacement therapy, radiation exposure to the breast,
obesity, and race/ethnicity (American Cancer Society, 2015; Ferlay et al., 2015). Breast cancer is
a heterogeneous disease characterized by up to 21 distinct histological subtypes and at least four
different molecular subtypes each with distinct presentations, response to treatment, and clinical
outcomes (American Cancer Society, 2015; Ferlay et al., 2015).
There has been marked improvement in the breast cancer survival rates and decline in deaths
owing to early detection, better understanding of the disease, and personalized treatment (Ferlay
et al., 2015). Current breast cancer treatment modality involves surgery (both curative and
preventive), radiation therapy, systemic chemotherapy, endocrine therapy, and targeted therapy
that interfere with the cellular functions thereby inducing cell cycle arrest and eventually apoptosis,
a form of programmed cell death (Gonzalez-Angulo et al., 2007; Florea and Busselberg, 2013).
However, breast cancer still remains the leading cause of death from cancer among women. The
most significant reasons for therapy failure are tumor metastases to distant sites and development
of treatment resistance (Gonzalez-Angulo et al., 2007; Florea and Busselberg, 2013). It is often
seen that metastatic and treatment resistant cells lose control over apoptosis and thus fail to die
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in response to various therapies. Identification of the mediators
and regulators of the apoptotic pathway may help to tailor
treatments for maximization of treatment efficacy leading
to complete tumor remission and prevention of metastases
(Kasibhatla and Tseng, 2003).
Recently, microRNAs (miRNAs) have emerged as critical
regulators of apoptosis. miRNAs are small non-coding RNAs
(∼18–25 bases) regulating gene expression at the post-
transcriptional and/or translational levels. Traditionally, they
are known to bind to the 3′ untranslated region of the target
transcript to bring about transcript degradation or inhibition of
translation depending on the extent of complementarity (Bartel,
2004). However, recent research suggests that miRNA may bind
anywhere in the transcript to regulate its levels and can also bring
about increase in the transcript levels by various mechanisms
(Antonio et al., 2006). It is increasingly becoming clear that
miRNAs generate a complex network with mRNAs, snoRNAs,
long non-coding RNAs, and RNA binding proteins to establish
cellular transcriptome (Mattick and Makunin, 2006).
The generation of miRNA profiles of normal or patient
samples using microarray, qPCR, or deep sequencing
technology and its analyses has helped in identifying useful
clinical correlations of miRNAs with potential applications
in cancer diagnosis, prognosis or therapy (Hammond, 2006).
Several human miRNAs have been reported to be significantly
deregulated in at least one cancer type and have been shown
to function as oncomiRs or tumor suppressor miRs. Such
deregulation of miRNA expressions across various tumor types
suggests that these miRNAs may be involved in crucial cellular
pathways that are commonly deregulated in cancer development.
In this review, we will focus on the recent progress of research
on miRNA-mediated regulation of apoptosis in breast cancer,
discuss pro- and anti-apoptotic miRNAs (ApoptomiRs), miRNA
targets, and their interaction with the p53 pathway. Finally, we
will discuss current/future cancer prognostics and treatment
targets based on these apoptotic regulators.
BREAST CANCER AND APOPTOSIS
A critical balance between cell proliferation and apoptosis
is essential for normal breast development. Accumulation of
genetic or epigenetic mutations by various factors brings about
disturbance in this balance leading to the development of
breast tumors. Breast tumors are heterogeneous in their genetic
composition and are histologically diverse based on receptor
status, proliferation and differentiation markers that correlate
to disease prognosis (Vakkala et al., 1999). The histological
analyses guide clinicians in selecting adjuvant therapies for breast
cancer treatment. Several studies have made attempts to correlate
apoptosis and its associated molecular markers with known
histologic and prognostic factors in breast cancer (Lipponen
et al., 1994). A high apoptotic index has been correlated with
increased tumor grade, aneuploidy, high mitotic index, negative
status for estrogen receptor (ER), and progesterone receptor
(PR), tumor necrosis and increased lymphocyte infiltration
(Lipponen, 1999). The tumor suppressor gene, p53, and the
BCL2 family have been widely studied in breast cancer. The
mutant p53 correlates with negative ER status, high mitotic
index, and the tumor grade, while BCL2 expression correlates
to ER positive status, wild type p53, low mitotic index and low
grade (Megha et al., 2002). Strikingly, expression of BCL2 is seen
in∼80% of breast cancer patients. Contrary to expectations, high
apoptotic index is significantly associated to poor prognosis while
high BCL2 expression correlates to good prognosis of breast
cancer patients (Silvestrini et al., 1996). Possible explanations
may be that neither apoptotic index nor mutant p53 or BCL2
is independent predictor of survival in breast cancer patients.
High apoptosis index also correlates to high proliferative index
and negative ER status, which are poor prognostic factors. High
apoptotic index may also put selective pressure on tumor cells
leading to development of apoptosis resistant cells leading to
tumor progression and decreased survival in patients (Frenzel
et al., 2009). Similarly, BCL2, an estrogen regulated gene
correlates with positive ER status, a good prognostic feature.
Nevertheless, in vitro experiments with BCL2 overexpression or
silencing in breast cancer cells confirm its pro-survival effects
accounting for current pre-clinical and clinical trials involving
BCL2 silencing for breast cancer treatment (Honma et al., 2015).
Breast cancer cells show activation of the upstream apoptotic
signaling such as an increase in Fas-L expression and presence
of active caspases in cancer cells (Hengartner, 2001; Fulda and
Debatin, 2006). However, upregulation of Inhibitors of apoptosis
proteins (IAPs), X-linked inhibitor of apoptosis protein (XIAP),
and Survivin inhibits activity of the caspases and blocks apoptotic
signaling (Deveraux and Reed, 1999). Overall, the balance
between the concentrations of pro- and anti-apoptotic proteins
is an important regulatory factor for apoptotic regulation (Quail
and Joyce, 2013).
PRO- AND ANTI-APOPTOTIC miRNAs IN
BREAST CANCER
Deregulation of apoptosis is an important step in cancer as it
allows the genetically unstable cells to survive and accumulate
further mutations that eventually lead to tumorigenesis (Elmore,
2007). One of the mechanism by which miRNAs influence
tumor development is by regulation of proteins involved in
the apoptotic process. miRNAs that function to promote or
inhibit apoptotis are called pro- and anti-apoptotic miRNAs,
respectively. Table 1 enlists various miRNAs that have been
reported to function as pro- or anti-apoptotic miRNAs in breast
cancer.
Pro-ApoptomiRs
A total of 22 miRNAs have been reported so far to be
involved in the induction of apoptosis suggesting them to be
tumor suppressors. Tumor suppressor miRNAs prevent tumor
progression by negatively regulating the expression of genes
that promote cell proliferation, differentiation, migration, or
apoptosis. We evaluated the expression of pro-apoptomiRs in
breast cancer patients using StarBase software that analyzes
TCGA data (Li J. H. et al., 2014). The data set included 683
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TABLE 1 | List of apoptosis-associated miRNAs in breast cancer.
miRNA Target gene Function of miRNA Breast cancer cell
lines/in vivo models
Citation miRNA
Cancer/normal
Fold Change p-value
PRO-APOPTOTIC miRs
miR-7-5p PSME3 Inhibits cell proliferation and
induces apoptosis in vitro and in
vivo
MDA-MB-231, MCF7,
and nude mice
Shi et al., 2015 2.08 S
miR-15/16 RPS6KB1 Inhibits cell proliferation and
promotes cell cycle arrest and
caspase-3 dependent apoptosis
MDA-MB-231, MCF7 Janaki Ramaiah et al., 2014 1.71, 1.44 S, S
miR-15a-5p SNCG, CCNE1 Mediates cell cycle arrest and
promotes cell apoptosis
MDA-MB-231,
MDA-MB-231
Luo et al., 2013 1.71 S
miR-15a-3p BCL2L1 Inhibits the expression of BCL2L1
and activates caspase-3/7 activity
to promote apoptosis
MDA-MB-231 Druz et al., 2013 ND ND
miR-16-5p CCND1, BCL2,
METTL13
Decreases cell growth and
proliferation and induces
apoptosis. Repression of
METTL13 by miR-16 promotes
apoptosis of cancer cells
MCF7 Rivas et al., 2012 1.44 S
mir-24-2-5p BCL-2 mir-24-2-5p induces apoptosis by
targeting BCL-2
MCF7 Srivastava et al., 2011 ND ND
miR-26a MTDH, EZH2, MCL1 Induces cell apoptosis and
suppresses tumorigenesis in vivo
MCF7, MDA-MB-231,
and nude mice
Zhang et al., 2011; Gao
et al., 2013
0.72 S
Repression of MCL1 by miR-26a
suppresses cell growth and
proliferation
miR-26b SLC7A11 Impairs viability and induces cell
apoptosis
MCF7 Liu X. X. et al., 2011 0.83 S
miR-31 PRKCE (PKCǫ) Enhances cell apoptosis, inhibits
oncogenic NF-κB pathway and
brings about indirect
downregulation of BCL2
MCF10A,
MDA-MB-231.
Körner et al., 2013 1.07 NS
miR-34a BCL2, SIRT1, FRA1,
LMTK3, AXL,
NOTCH1, LDHA
Suppresses cells proliferation,
glycolysis, migration, invasion,
and induces apoptosis. Reduces
cancer stem cell properties and
increases sensitivity to
doxorubicin treatment.
MCF7, MDA-MB-231,
BT549, Hs578T, and
nude mice
Mackiewicz et al., 2011; Li
et al., 2013; Yang et al.,
2013; Zhao et al., 2013;
Park et al., 2014; Xiao et al.,
2016
1.09 NS
miR-124 Ets-1 Induces cell apoptosis, reduces
cell proliferation, and colony
formation.
MCF7, MDA-MB-231. Li W. et al., 2014 1.1 S
miR-125a ELAVL1 Promotes apoptosis and inhibits
cell growth and proliferation
MCF7 Guo et al., 2009 0.68 S
miR-125b MUC1, EPO, EPOR,
ENPEP, CK2-α, CCNJ,
MEGF9, ERBB2,
ARID3B
miR-125b promotes DNA
damage-induced apoptosis and
regulates cell motility
ZR-75-1, BT549,
MCF7, MDA-MB-231
Rajabi et al., 2010;
Akhavantabasi et al., 2012;
Feliciano et al., 2013;
Ferracin et al., 2013
0.27 S
miR-145 RTKN, c-Myc Induces cell apoptosis and
inhibits cancer cell growth
MCF7 Sachdeva et al., 2009;
Wang et al., 2009
0.17 S
miR-146a/b IRAK1, TRAF6 Mediates tumor suppression and
triggers apoptosis
MCF7 Liu et al., 2015 1.11, 1.54 NS, S
miR-290-3p ARID4B miR-290 enhances ER signaling
and increases apoptosis thereby
suppressing breast cancer
progression
6DT1, MVT-1 Goldberger et al., 2013 ND ND
(Continued)
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TABLE 1 | Continued
miRNA Target gene Function of miRNA Breast cancer cell
lines/in vivo models
Citation miRNA
Cancer/normal
Fold Change p-value
miR-486-5p PIM-1 Suppresses cell proliferation in
vitro and in vivo, induces G0/G1
arrest, and promotes apoptosis
MDA-MB-231, T47D
and nude mice
Zhang et al., 2014 0.07 S
miR-497 Bcl-w (Bcl2L2) Inhibits cellular growth and
enhances apoptosis, promotes
G0/G1 cell phase arrest
MCF7 Shen et al., 2012 0.38 S
miR-502-5p TRAF2 Enhances early apoptosis and
inhibits proliferation of breast
cancer cells
MCF7, MDA-MB-231,
and MCF-10A
Sun et al., 2014 ND ND
miR-769-3p NDRG1 Inhibits cell proliferation and
enhances apoptosis
MCF7 Luo et al., 2014 ND ND
miR-874 CDK9 Induces cell apoptosis and
inhibits cell proliferation and
brings about cell cycle arrest
MCF7, MDA-MB-231 Wang L. et al., 2014 0.77 S
miR-99a mTOR Induces cell apoptosis and
suppresses cell viability
MCF7, MDA-MB-231 Hu et al., 2014 0.22 S
ANTI-APOPTOTIC miRs
miR-21 BCL2, TIMP3, PDCD4,
PTEN, TPM1, MASPIN,
ANKRD46
miR-21 inhibition suppress both
cell growth in vitro and tumor
growth in vivo miR-21 promotes
invasion in breast cancer cells
MCF7, MDA-MB-231,
MDA-MB-435, and
nude mice
Zhu et al., 2007; Frankel
et al., 2008; Yang et al.,
2009; Song et al., 2010;
Wang et al., 2011; Yan
et al., 2011
4.81 S
miR-24-3p p27Kip1 Promotes cell proliferation and
inhibits cell apoptosis
MDA-MB-435,
MDA-MB-468
Lu et al., 2015 0.94 NS
miR-100 MTMR3 Antagonism of miR-100 led to
G2/M cell-cycle arrest and induce
apoptosis
SK-BR-3 He et al., 2015 0.23 S
miR-155 FOXO3a, SOCS1,
RHOA
Induces cell survival and plays an
important role in chemoresistance
in breast cancer.
MCF7, MDA-MB-231 Kong et al., 2008, 2010;
Jiang et al., 2010
2.24 S
miR-155 TP53INP1 miR-155 mediates cell
proliferation and inhibits cell
apoptosis
MCF7 Zhang et al., 2013 2.24 S
miR-96/182 PFN1, FOXO1 miR-182 promotes proliferation
and invasion and inhibits
apoptosis of breast cancer cells
MDA-MB-231, MCF7 Guttilla and White, 2009; Liu
et al., 2013
miR-182 (5.31) S
miR-96 (7.35) S
miR-196a ANXA1 Enhances cell proliferation, colony
formation and suppresses
apoptosis
T47D, MDA-MB-453,
MDA-MB-231
Luthra et al., 2008 5.12 S
miR-
221/222
PTEN, PUMA, CASP3,
p27Kip1
Enforced expression of
miR-221/222 promotes breast
cancer cell proliferation, migration
and invasion and inhibits
apoptosis by targeting and
blocking caspase-3 expression
MCF7, SKBR3,
HCC1500, MDA-MB-
231,
Miller et al., 2008; Zhang
et al., 2010; Ergun and
Oztuzcu, 2014; Li et al.,
2016
miR-221 (0.81),
miR-222 (0.79)
S, S
miR-210 RAD52, GPD1L miR-210 overexpression inhibits
apoptosis
MCF7 Crosby et al., 2009;
Fasanaro et al., 2009
5.46 S
miR-504 P53 miR-504 overexpression reduces
p53 mediated apoptosis and cell
cycle arrest in response to stress
MCF7 and nude mice Hu et al., 2010 0.73 S
breast cancer patients and 87 normal samples. Interestingly, we
found that miR-26a, -26b, -125a, -125b, -145, -486-5p, -497,
-874, and -99a that are known to function as proapoptomiRs
were significantly downregulated in breast cancer patients. In
the following section, we have discussed some pro-apoptotic
miRNAs.
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miR-15/16 Cluster
miR-15/16 was shown to inhibit cell proliferation and promote
cell cycle arrest and apoptosis in various breast cancer cell
lines (Rivas et al., 2012; Druz et al., 2013; Luo et al., 2013;
Janaki Ramaiah et al., 2014). The members of miR-15/16 cluster
negatively regulate the anti-apoptotic protein BCL2, cell cycle
regulators CCND1, CCNE1 and other proteins RPS6KB1, SNCG
and METTL13 in breast cancer (refer Table 1).
miR-26a/b
miR-26a is downregulated in breast cancer specimens and cell
lines and its transient transfection initiates apoptosis of breast
cancer cell line, MCF7. Oncogenes, MTDH, and EZH2 (a
chromatin regulator), were identified as direct targets of miR-
26a. MCF7 xenografts with exogenous miR-26a show that a
decrease in expression of both MTDH and EZH2 is accompanied
by an increase in apoptosis (Zhang et al., 2011). MCL1, an
anti-apoptotic member of the BCL2 family and SLC7A11, an
amino acid transporter are other targets of miR-26a (Gao et al.,
2013). Silencing of SLC7A11 mimics miR-26b aroused viability
impairment and apoptosis in MCF7 cells.
miR-34a
Several groups have independently reported pro-apoptotic role
of miR-34a in breast cancer (Mackiewicz et al., 2011; Li et al.,
2013; Yang et al., 2013; Zhao et al., 2013; Park et al., 2014; Xiao
et al., 2016). miR-34 overexpression suppresses cell proliferation,
glycolysis, metastasis, invasion, stem cell properties, and
promotes apoptosis and sensitivity to doxorubicin treatment in
breast cancer (Mackiewicz et al., 2011; Li et al., 2013; Yang et al.,
2013; Zhao et al., 2013; Park et al., 2014; Xiao et al., 2016). miR-
34a is transcriptionally regulated by p53 and targets SIRT1 (a
modulator of p53 activity) thus making a mir-34-p53 positive
feedback loop (Li et al., 2013). Other targets of miR-34a are
BCL2, FRA1, LMTK3, AXL, NOTCH1 and LDHA.miR-34a/AXL
interaction reduces phospho-AKT expression, and impairs the
motility of triple-negative breast cancer cells (Mackiewicz et al.,
2011). miR-34a suppresses MCF7 cell proliferation in vitro and
in vivo by targeting LMTK3 in an estrogen dependent manner
(Zhao et al., 2013). Overall, miR-34a functions as a tumor
suppressor in breast cancer as also reported for other cancers.
miR-125a/b
miR-125a/b promotes apoptosis and inhibits cell growth and
proliferation. miR-125a functions as a tumor suppressor for
breast cancer, with HuR as a direct and functional target (Guo
et al., 2009). miR-125b perform its tumor suppressor function
via the direct targeting of the 3′-UTRs of ENPEP, CK2-α,
CCNJ, MUC1, and MEGF9 mRNAs. miR-125b regulates cell
motility by targeting ERBB2 and ARID3B (Rajabi et al., 2010;
Akhavantabasi et al., 2012; Feliciano et al., 2013; Ferracin et al.,
2013). Overexpression of miR-125b markedly inhibits Taxol-
induced cell cytotoxicity in MDA-MB-435, MDA-MB-231, and
BT474 breast cancer cells by targeting 3′UTR of BAK1 mRNA,
which is an effector of taxol induced apoptosis (Zhou et al.,
2010).
Anti-ApoptomiRs
A total of 11 miRNAs have been shown to inhibit apoptosis
suggesting them to be oncomiRs in breast cancer. Among these
miR-21, -155, -96, -182, -196a, and -210 were found to be highly
upregulated in breast cancer patients (Table 1).
miR-21
miRNA 21 is overexpressed in many cancers and has been shown
to have oncogenic activity. Si et al., 2007 showed that miR-21
knock down inhibits MCF7 cell growth in vitro and suppresses
MCF7 cell derived breast tumor growth in a murine xenograft
model (Si et al., 2007). This was associated with increased
apoptosis and decreased cell proliferation by downregulation of
anti-apoptotic BCL2. miR-21 was also shown to promote breast
cancer cell invasion. Overall, miR-21 functions as an oncomiR
andmodulates tumorigenesis through regulation of genes such as
ANKRD46, BCL2, TIMP3, PDCD4, PTEN, TPM1, and MASPIN
in breast cancer (Zhu et al., 2007; Frankel et al., 2008; Yang et al.,
2009; Song et al., 2010; Wang et al., 2011; Yan et al., 2011).
miR-155
miR-155 exerts its anti-apoptotic activity by downregulating
FOXO3a for cell survival (Kong et al., 2010). Active form of
FOXO3a resides in the nucleus and induces cell death by up-
regulation of apoptotic proteins, such as BIM, p27, BNIP3, and
24p3 and repression of anti-apoptotic proteins, FLIP, and BCL-
xL (Kong et al., 2010). miR-155 also targets TP531NP1, SOCS1,
and RHOA and inhibits apoptosis and chemosensitivity inMCF7
cells (Kong et al., 2008, 2010; Jiang et al., 2010; Zhang et al., 2013).
miR-210
miR-210 is a hypoxia inducible miRNA that functions as an
oncomiR in breast cancer. High miR-210 expression is a poor
prognostic factor in breast cancer patients. miR-210 inhibition
promotes apoptosis in breast cancer. It is known to target DNA
repair protein RAD52 and a protein involved in mitochondrial
function regulation, GPD1L (Crosby et al., 2009; Fasanaro et al.,
2009).
miR-221/222
miR-221/222 are frequently up-regulated in human epithelial
cancers. Enforced expression of miR-221/222 promotes breast
cancer cell proliferation, migration, and invasion via targeting
PTEN/AKT pathway. In breast cancer miR-221/222 directly
targets pro-apoptotic proteins PUMA and CASP3 and cell
cycle inhibitor, p27Kip1 to show its oncogenic effect (Zhang
et al., 2010). miR-221/222 inhibition results in an increase
in mitochondrial membrane potential and caspase-3/7 activity
thereby leading to apoptosis in the A549 and MCF7 cell lines
(Zhang et al., 2010).
TARGETS OF ApoptomiRs
A total of 61 genes have been validated as direct targets of
apoptomiRs. Interestingly, ∼36% of these targets were found to
be altered at the transcript (BCL2, CCNE1, CSKN2A1, ELAVL1,
ERBB2, ETS1, EZH2, FOXO1, IRAK1, MUC1, MYC, NDRG1,
PDCD4, SERPINB5, RPS6B1, SNCG, TIMP3, TP53, and
TP53INP1) or the protein (BCL2, CASP3, CCNE1, CDKN1B,
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ERBB2, MUC1, MYC, PTEN, SERPINB5, TP53) levels in breast
cancer based on analyses using genes to system breast cancer
(G2SBC) database (Mosca et al., 2010). Whether the effects of
the miRNAs on apoptosis are mediated through these targets
has not been fully elucidated. Pathway analyses of the target
genes of apoptomiRs using Reactome pathway browser identified
transcriptional regulation by TP53 (CCNE1, CDKN1B, mTOR,
CDK9, CSKN2A1, NDRG1, PTEN, PUMA, TP53, TP53INP1);
signaling by nerve growth factor, NGF (IRAK1, ERBB2, CASP3,
CDKN1B, RHOA, mTOR, FOXO1, PSME3, FOXO3, PRKCE,
TRAF6, PTEN); and PI3K/AKT activation (CDKN1B, ERBB2,
RHOA, mTOR, FOXO1, FOXO3, PTEN) as the top three
overrepresented pathways (Joshi-Tope et al., 2005). NGF is
known to be overexpressed in ∼80% of breast tumor biopsies
and has been implicated in enhanced survival, proliferation,
migration, and inhibition of apoptosis in breast cancer (Molloy
et al., 2011). Similarly, the pro-proliferative and anti-apoptotic
effects of PI3K/AKT pathway are well documented. A protein
interaction network analyses using STRING database (Von
Mering et al., 2005) reveals that a strong interaction network with
a high confidence (0.7) exists between the validated targets of the
apoptomiRs suggesting that this set of the genes are biologically
related (Figure 1).
Interestingly, around 40% of the apoptomiR targets (BCL2,
BCL2L1, BCl2L2, FOSL1, NOTCH1, TIMP3, TRAF2, TRAF6,
ANXA1, CASP3, CDKN1B, FOXO1, FOXO3, IRAK1, MCL1,
PTEN, PIM1, PSME3, PRKCE, PUMA, RHOA, SIRT1, TP53,
TP53INP1, ERBB2, and ETS1) were found to be associated
with regulation of apoptosis based on functional annotation
clustering using DAVID microarray software (Huang et al.,
2009a,b). Several of these belong to the p53 network or BCL2
family of proteins involved in control of apoptosis.
p53, is a tumor suppressor protein that mediates cellular
responses to various stress signals like DNA damage, hypoxia,
or aberrant oncogene expression by promoting cell-cycle
checkpoints, DNA repair, cellular senescence, and apoptosis. In
breast cancer, TP53 mutations have been associated with poor
response to various therapies and thus poor prognosis. Several
miRNAs were found to be associated with the p53 network by
targeting p53 directly or indirectly (by targeting its upstream
regulators or downstream mediators) to influence apoptosis in
breast cancer. miR-504 was shown to directly target p53 and
thus, inhibit p53 dependent apoptosis in breast cancer (Hu et al.,
2010). MDM2 is an E3 ubiquitin-protein ligase that mediates
ubiquitination of p53, leading to its proteasomal degradation
and nuclear export. miR-143/145, and miR-1827 were found to
directly target MDM2 in breast cancer and thus enhance p53-
mediated stress responses, including apoptosis and senescence
(Okamura et al., 2001). TP53INP1, SIRT1, and EGR1, regulators
of p53 transcriptional activity, have also been shown to be
direct targets of apoptomiRs- miR-155, miR-34, and miR-191,
respectively, in breast cancer (Li et al., 2013; Nagpal et al., 2013;
Zhang et al., 2013). Similarly, several miRNAs (miR-9, miR-
17/20, 21, 125b, 155, 203, 222, and 342) affect the levels of
p53 downstream genes to establish their effect on apoptosis.
Additionally, p53 has been shown to induce the levels of several
miRNAs involved in regulation of apoptosis in breast cancer.
A total of six tumor suppressor miRNAs (miR-143, miR-145,
miR-15, miR-16, miR-26a, and miR-34) have been shown to be
upregulated by p53 in breast cancer (Sachdeva et al., 2009; Gao
et al., 2013; Li et al., 2013; Janaki Ramaiah et al., 2014). Since miR-
143/145 regulate MDM2 (regulator and transcriptional target of
p53) and are also regulated by p53, it indicates existence of miR-
143/145-MDM2-p53 feedback loop in breast cancer that controls
cell proliferation and apoptosis (Okamura et al., 2001). Similarly,
miR-34 is induced by p53 and targets SIRT1 (a modulator
of p53 activity) thus making a mir-34-p53 positive feedback
loop (Yamakuchi et al., 2008). Overall, apoptomiRs emerge as
important regulators of the p53 network at multiple levels to
regulate apoptosis in breast cancer (Figure 2).
A number of BCL2 family members were found to be targeted
by apoptomiRs by various groups. BCL2 family consists of both
pro and anti-apoptotic proteins. BCL2, an antiapototic protein,
was found to be targeted by four miRNAs (miR-21, -24, -
34a, and -16) indicating that its levels are kept under tight
control in breast tissue. Overexpression of miR-24, 34a, and
16 reduces BCL2 expression that leads to apoptosis through
disruption of the mitochondrial membrane potential and the
release of cytochrome C (Srivastava et al., 2011; Rivas et al.,
2012; Li et al., 2013). Other anti-apoptotic members of the
BCL2 family are also directly targeted by apoptomiRs- (BCL2L1-
mir-15a-3p, BCL2L2- miR-497, MCL1- miR-26a; Shen et al.,
2012; Druz et al., 2013; Gao et al., 2013). The level of BAK1,
a pro-apoptotic BCL2 family protein, was found to be a direct
target of oncomiR, miR-125b. PUMA, belonging to the BH3-only
subgroup of BCL2 family protein was also found to be targeted
by miR-221/222 (Zhang et al., 2010). miR-17/20 transduction
of MCF7 cells has been shown to induce p53 and apoptosis
characterized by activation of BAX, release of cytochrome C, and
induction of BCL-X(S) in response to DNA damaging agents,
like doxorubicin and tamoxifen. Overall, a multipronged attack
by miRNAs seems to directly or indirectly target BCL2 family
proteins or downstream targets in breast cancer.
CASP3 is a mediator of apoptosis that gets activated in
apoptotic cell by both death ligand (extrinsic) and mitochondrial
(intrinsic) pathways. It was found to be a direct target of miR-
221/222 in breast cancer (Miller et al., 2008). Several cell cycle
related genes (CCND1, CCNE1, CCNJ, CDK9, CDKN1B, and
PSME3) also feature in the list suggesting important roles these
apoptomiRs may play in maintaining balance between apoptosis
and cell cycle. Finally, apoptomiRs target crucial genes involved
mainly in the apoptotic or cell cycle related pathways in breast
cancer. Fishing out more targets using advanced technologies
will likely widen the range of the pathways affected by these
targets.
miRNAs and Drug Resistance in Breast
Cancer
The commonly used drugs for breast cancer treatment
are Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin,
Methotrexate, Paclitaxel, Cisplatin, Carboplatin, 5 Fluorouracil,
Gemcitabine, etc. The patients are also given treatment based
on the receptor status. The patients are tested for ER, Her2,
and PR status. ER+ve patients receive tamoxifen (antagonist
of ER signaling) and Her2+ve patients receive trastuzumab
(herceptin), a monoclonal antibody against Her2, included in
Frontiers in Genetics | www.frontiersin.org 6 September 2016 | Volume 7 | Article 175
Sharma et al. ApoptomiRs of Breast Cancer: Basics to Clinics
FIGURE 1 | Pathway interaction network of targets of apoptomiRs in breast cancer. STRING interaction database (Von Mering et al., 2005) was used at
setting of high confidence (0.7) to generate the interaction network of the list of the targets of apoptomiRs in breast cancer (Zhu et al., 2007; Frankel et al., 2008; Kong
et al., 2008; Luthra et al., 2008; Miller et al., 2008; Crosby et al., 2009; Fasanaro et al., 2009; Guo et al., 2009; Guttilla and White, 2009; Sachdeva et al., 2009; Wang
et al., 2009; Yang et al., 2009; Hu et al., 2010; Jiang et al., 2010; Kong et al., 2010; Rajabi et al., 2010; Song et al., 2010; Zhang et al., 2010; Liu X. X. et al., 2011;
Mackiewicz et al., 2011; Srivastava et al., 2011; Wang et al., 2011; Yan et al., 2011; Zhang et al., 2011; Akhavantabasi et al., 2012; Rivas et al., 2012; Shen et al.,
2012; Druz et al., 2013; Feliciano et al., 2013; Ferracin et al., 2013; Gao et al., 2013; Goldberger et al., 2013; Körner et al., 2013; Li et al., 2013; Liu et al., 2013; Luo
et al., 2013; Yang et al., 2013; Zhang et al., 2013; Zhao et al., 2013; Ergun and Oztuzcu, 2014; Hu et al., 2014; Janaki Ramaiah et al., 2014; Luo et al., 2014; Li W.
et al., 2014; Park et al., 2014; Sun et al., 2014; Wang L. et al., 2014; Zhang et al., 2014; He et al., 2015; Liu et al., 2015; Lu et al., 2015; Shi et al., 2015; Li et al.,
2016; Xiao et al., 2016). The implication of the various connective lines based on different data sources are shown below the figure.
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FIGURE 2 | miRNAs in red color correspond to the miRNAs that regulate p53 in breast cancer and miRNAs in blue color corresponds to the miRNAs
that are regulated by p53 in breast cancer. Arrow indicates activation and bar indicates inhibition. The references for each miRNA are marked as superscript in
green color. 25(Druz et al., 2013), 26(Rivas et al., 2012), 27(Srivastava et al., 2011), 28(Zhang et al., 2011), 32(Li et al., 2013), 42(Feliciano et al., 2013), 56(Frankel et al.,
2008), 65(Zhang et al., 2013), 70(Zhang et al., 2010), 87(Hu et al., 2010), 88(Okamura et al., 2001), 89(Nagpal et al., 2013), 100(Ru et al., 2011), 103(He et al., 2013),
107(Yu et al., 2014), 154(Zhang et al., 2016), 155(Zhou et al., 2015).
the chemotherapy regimen (Osborne, 1998; Ariazi et al., 2006).
While the response of breast cancer patients to radiation, drug,
or hormonal treatment has considerably improved the patient
disease free survival and overall survival, chances of recurrence
still remain. Since apoptosis mediated cancer cell death remains
central to all the treatment strategies, the recurrence has been
attributed to the development of resistance to apoptotic death
and maintenance of cell viability by undergoing viable cellular
responses such as cellular senescence (generates secretomes
which can directly enhance the malignant phenotype) or
autophagy (a state of reversible dormancy making it possible for
cancer cells to survive and regrow at a later stage; Degenhardt
et al., 2006).
Several mechanisms of chemoresistance in breast cancer have
been reported in breast cancer such as upregulation of the
ATP-binding cassette (ABC) transporters, drug inactivation or
detoxification, alterations in genes related to cell cycle, apoptosis
or DNA repair enzymes, epigenetic modifications, and activation
of signaling pathways related to the progression of cancer
(Baker et al., 2005; Pogribny et al., 2010). Recently, alterations
of miRNA levels too have been linked to the development of
drug resistance in breast cancer (Kovalchuk et al., 2008; Baylin,
2011). Very few miRNAs (miR-17/20, -21, -34a, -125b, -181a,
-203, -218, -221, -222, -342) have been reported till date to
affect the sensitivity to drugs (paclitaxel, cisplatin, doxorubicin,
and taxol) or hormonal (tamoxifen and trastuzumab) treatment
in various breast cancer cell lines (Table 2). These miRNAs
affect the drug sensitivity by interfering in apoptotic death by
affecting the levels of various apoptotic regulators (TP53, BCL2,
BAX, BAK1, SURVIVIN, NOTCH1), members or regulators of
AKT signaling pathway (AKT1, PTEN), ID4, NOTCH1 and
SOCS3. Considering that the levels of several miRNAs change
in response to drug treatment or are differentially regulated
between sensitive versus resistant breast cancer cell lines, it is very
likely that the list of miRNAs associated with drug resistance will
expand. Some of these miRNAs may also function as biomarkers
in predicting and monitoring drug response in breast cancer
patients (Nana-Sinkam and Croce, 2013). These miRNAs are
also being evaluated for their use in combination therapies to
counteract drug resistance (Nana-Sinkam and Croce, 2013).
ApoptomiRs AS BIOMARKERS AND
THERAPEUTIC TARGETS IN BREAST
CANCER
Early detection of breast cancer is important to reduce the
risk of disease. Current diagnostic methods for early detection
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TABLE 2 | miRNAs associated with drug resistance in breast cancer.
miRNA Drug Targets Cell lines/in vivo models Citation
miR-125b Paclitaxel (Taxol) Bcl-2 antagonist killer 1 (Bak1) is a direct target of
miR-125b. miR-125b confers Taxol resistance through
suppression of Bak1 expression
MDA-MB-435, MDA-MB-231,
MDA-MB-436, MCF7, SKBR3,
and BT474
Zhou et al., 2010
miR-203 Cisplatin Knockdown of miR-203 sensitized human breast cancer
MCF7 cells to cisplatin-mediated apoptotic cell death
MCF7, ZR-75, and MDA-MB-231 Ru et al., 2011
SOCS3 is a novel target of miR-203 and plays an important
role in cisplatin sensitivity of breast cancer cells
miR-21 Doxorubicin(ADR) Dysregulation of miR-21 plays critical roles in the ADR
(doxorubicin) resistance of breast cancer via targeting PTEN
MCF7 Wang et al., 2011
MIR-34a Doxorubicin(ADR) Ectopic miR-34a expression reduces cancer stem cell
properties and increases sensitivity to doxorubicin
treatment by directly targeting NOTCH1
MCF7 Li et al., 2012
miR-342 Tamoxifen Overexpression of miR-342 upregulates the expression of
ER-α mRNA and sensitizes the MCF7 cells to tamoxifen.
miR-342 is down-regulated in breast tumors resistant to
Tamoxifen. Reintroduction of miR-342 sensitizes refractory
breast tumor cells to tamoxifen therapy. ID4 was identified
as a putative target of miR-342
MCF7, BT20,
MDA-MB-231,T47D, HCC1937
He et al., 2013;
Crippa et al., 2014
miR-221/222 Trastuzumab miR-221 mediated downregulation of PTEN confers
trastuzumab resistance of HER2-positive breast cancers
SKBR3 and nude mice Ye et al., 2014
miR-181a Adriamycin miR-181a regulates the chemosensitivity to Adriamycin by
targeting BCL2 in MCF7 and MCF7/ADR cells
MCF7 Zhu et al., 2013
miR-17/20 Doxorubicin and Tamoxifen miR-17/20 sensitized breast cancer cells to
chemotherapy-induced apoptosis requires AKT1
MCF7 Yu et al., 2014
miR-218 Doxorubicin and Taxol miR-218 is involved in the development of multi drug
resistance in breast cancer cells via targeting SURVIVIN
leading to evasion of apoptosis
MCF7 and nude mice Hu et al., 2015
of breast cancer are still limited to some procedures such as
tissue biopsies and histological examination using mRNA or
protein biomarkers. However, there is still need for sensitive and
specific markers. As miRNAs have small size, high specificity, and
greater stability, they can be used as biomarkers with diagnostic
(based on their ability to discriminate between normal and breast
cancer patients), predictive [which are involved in response
(sensitivity/resistance) to conventional breast cancer therapeutic
strategies] or prognostic (which predict patient overall or disease-
free survival) potential (Krutovskikh and Herceg, 2010; Abba
et al., 2012; Schooneveld et al., 2015). Several studies have shown
the role of miRNAs in diagnosis and prognosis of breast cancer.
Iorio et al. (2005) identified a 13 miRNA signature that could
differentiate breast cancer from normal breast tissue with 100%
accuracy (Iorio et al., 2005). Blenkiron et al. (2007) identified
133 miRNAs that displayed aberrant expression levels in breast
tumor tissues compared with normal breast tissues (Blenkiron
et al., 2007). Recently several reports suggested that circulating
miRNAs are highly stable in serum/plasma and levels of some
miRNAs are specifically elevated in patients with breast cancer
(Heneghan et al., 2010). In a recent study, nine circulating
miRNAs were shown to be capable of discriminating between
early-stage breast cancer and healthy controls (Kodahl et al.,
2014). Another study reported three significantly overexpressed
serum miRNAs in breast cancer patients as compared to breast
cancer free controls (Ng et al., 2013). Recently, Bertoli et al.
(2015) and Schooneveld et al. (2015) reported circulating and
non-circulating miRNAs as breast cancer biomarkers. Several of
the apoptomiRs have also been shown to serve as biomarkers in
breast cancer (Abba et al., 2012; Bertoli et al., 2015; Figure 3).
While some apoptomiRs have only diagnostic (miR-15a/16, -
17, -181a, -145, -146) or predictive (miR-26a/b, -181b, -502) or
prognostic (miR-497) potential, some have been proposed to
serve as biomarkers for any two (miR-7, -34, -125a/b, -155, -222,
-342) or all the three purposes (miR-21). Based on their presence
and high stability in patient serum, capacity to reflect tumor
status, and high clinical outcome, some apoptomiRs (miR-155,
-21, -16, -222, and -210) are present as circulating miRNAs and
can be used as potential biomarkers for breast cancer. miR-210 is
a hypoxia regulated anti-apoptotic miRNA in breast cancer and
high miR-210 baseline expression has been associated with poor
prognosis and resistance to trastuzumab-included chemotherapy
(Jung et al., 2012) High miR-155 levels too have been reported
in tumor tissues sections and the serum of breast cancer patients
and have been correlated to poor prognosis (Kong et al., 2014).
Similarly, miR-21 upregulation is associated with taxol resistance
and poor prognosis in breast cancer cells (Mei et al., 2010). miR-
34 has been proposed to serve as a predictive marker for response
to radiotherapy (Stankevicins et al., 2013). Kato et al. reported
that low levels of miR-34a rendered breast cancer cells more
resistant to radiotherapy (Kato et al., 2009).
While successful miRNA delivery still remains a challenge,
the prospects of using miRNAs as means and targets for
breast cancer therapy remain attractive. There are two lines of
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FIGURE 3 | Diagram showing apoptosis related miRNAs that are identified as biomarkers in breast cancer. The references for each miRNA are marked as
superscript in red color. 32(Li et al., 2013), 112(Iorio et al., 2005), 116(Ng et al., 2013), 118(Jung et al., 2012), 122(Kato et al., 2009), 128(Foekens et al., 2008),
129(Kodahl et al., 2014), 130(Volinia et al., 2006), 131(Wang F. et al., 2014), 132(Godfrey et al., 2013), 133 (Lyng et al., 2012), 134 (Chen and Bourguignon, 2014),
135(Mei et al., 2010), 136(Maillot et al., 2009), 137 (Stankevicins et al., 2013), 138(Valabrega et al., 2007), 139(Zhao et al., 2008), 140 (Wei et al., 2014), 141(Gan et al.,
2014), 142(Rao et al., 2011), 143 (He et al., 2013), 144(Cittelly et al., 2010), 145(Lee et al., 2011), 146(Song et al., 2012), 147 (Kong et al., 2014), 148(Volinia et al., 2012),
149 (Li M. et al., 2014), 150(Wang J. et al., 2014), 151(Leivonen et al., 2014), 152(Shen et al., 2012), 153(Wang et al., 2013).
action for therapeutic use of miRNAs: miRNA antagonists for
miRNA inhibition and miRNA mimics for miRNA replacement
therapy (Bader, 2012; Thorsen et al., 2012). Based on in
vitro studies several miRNAs have reached preclinical trials
and two miRNAs, have entered clinical trials. A locked
nucleic acid-based antisense oligonucleotide against miR-122
(Miravirsen), successfully completed phase I clinical study and
is undergoing phase II clinical trials for treatment of chronic
hepatitis C virus infection (Janssen et al., 2013). In preclinical
studies, Liu et al. reported that the injection of miR-34a mimic
extended the survival of tumor-bearing mice (Liu C. et al.,
2011). Another study demonstrated that systemic administration
of miR-34 in a pancreatic xenograft cancer model significantly
inhibited tumor growth and induced cancer cell apoptosis (Hu
et al., 2013). A clinical trial using miR-34 mimic (MRX34) has
already entered phase I clinical trial in patients with unresectable
primary liver cancer or metastatic cancer with liver involvement
(ClinicalTrials.gov Identifier: NCT01829971). Considering that
miR-34 plays a major role in breast tumorigenesis and shows
promising results in preclinical trials, miR-34 may soon enter
clinical trials for treatment of breast cancer patients.
CONCLUSIONS
Mechanisms of cell death and its regulation during initiation,
progression, and treatment of breast cancer are complex and
still remain partially understood. The role of miRNAs as critical
mediators of apoptotic cell death has been a revelation in the
past decade and has given us means to manipulate cell death for
breast cancer treatment or for disease monitoring. The current
impediments for successful treatment are miRNA delivery issues,
concerns over off-target effects and our incomplete knowledge of
the functions of these miRNAs. Many of these miRNAs may have
uninvestigated roles in other forms of cell death that may change
the output based on the balance between the desired (apoptosis)
and undesired (autophagy and necrosis) forms of cell death for
breast cancer treatment. Nevertheless, miRNA delivery issues
are slowly getting resolved, miRNAs are also being considered
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as means to target multiple aberrant pathways and certainly
preclinical and clinical trials of some of these miRNAs look
promising. The pool of apoptomiRs in breast cancer is likely to
get bigger with advanced technologies such as large scale miRNA
functional screens using 3D tumor models, thus giving us more
probable candidates as novel targets for breast cancer therapy.
AUTHOR CONTRIBUTIONS
RK conceptualized the theme of the review and has written
the review. SS compiled all the data on pro- and anti-apoptotic
miRNAs and their correlation to drug resistance and has
contributed in writing the review. PP and SA compiled the data of
miRNA and p53 regulatory loop and contributed toward writing
this section.
ACKNOWLEDGMENTS
This work was supported by the grant SB/S0/BB-0088/2013 from
Science and Engineering Research Board, Department of Science
& Technology, Government of India to RK. SS thanks Centre for
Scientific and Industrial Research for Senior Research Fellowship.
REFERENCES
Abba, M., Mudduluru, G., and Allgayer, H. (2012). Micrornas in cancer: small
molecules, big chances. Anticancer Agents Med. Chem. 12, 733–743. doi:
10.2174/187152012802650273
Akhavantabasi, S., Sapmaz, A., Tuna, S., and Erson-Bensan, A. E. (2012). miR-
125b targets ARID3B in breast cancer cells. Cell Struct. Funct. 37, 27–38. doi:
10.1247/csf.11025
American Cancer Society (2015). Breast Cancer Facts& Figures 2015-2016.Atlanta:
American Cancer Society.
Antonio, M., Sanchez, V., Liu, J., Hannon, G. J., and Parker, R. (2006). Control
of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20,
515–524. doi: 10.1101/gad.1399806
Ariazi, E. A., Ariazi, J. L., Cordera, F., and Jordan, V. C. (2006). Estrogen receptors
as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 6, 181–202. doi:
10.2174/156802606776173483
Bader, A. G. (2012). miR-34 - a microRNA replacement therapy is headed to the
clinic. Front. Genet. 3:120. doi: 10.3389/fgene.2012.00120
Baker, E. K., Johnstone, R. W., Zalcberg, J. R., and El-Osta, A. (2005). Epigenetic
changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene
24, 8061–8075. doi: 10.1038/sj.onc.1208955
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116, 281–297. doi: 10.1016/S0092-8674(04)00045-5
Baylin, S. B. (2011). Resistance, epigenetics and the cancer ecosystem. Nat. Med.
17, 288–289. doi: 10.1038/nm0311-288
Bertoli, G., Cava, C., and Castiglioni, I. (2015). MicroRNAs: new biomarkers for
diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer.
Theranostics 5, 1122–1143. doi: 10.7150/thno.11543
Blenkiron, C., Goldstein, L. D., Thorne, N. P., Spiteri, I., Chin, S. F., Dunning, M. J.,
et al. (2007). MicroRNA expression profiling of human breast cancer identifies
new markers of tumor subtype. Genome Biol. 8:R214. doi: 10.1186/gb-2007-8-
10-r214
Chen, L., and Bourguignon, L. Y. (2014). Hyaluronan-CD44 interaction promotes
c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and
chemoresistance in breast cancer cells. Mol. Cancer 13:52. doi: 10.1186/1476-
4598-13-52
Cittelly, D. M., Das, P. M., Spoelstra, N. S., Edgerton, S. M., Richer, J. K., et al.
(2010). Downregulation of miR-342 is associated with tamoxifen resistant
breast tumors.Mol. Cancer 9:317. doi: 10.1186/1476-4598-9-317
Crippa, E., Lusa, L., De Cecco, L., Marchesi, E., Calin, G. A., Radice, P., et al.
(2014). miR-342 regulates BRCA1 expression through modulation of ID4 in
breast cancer. PLoS ONE 9:e87039. doi: 10.1371/journal.pone.0087039
Crosby, M. E., Kulshreshtha, R., Ivan, M., and Glazer, P. M. (2009). MicroRNA
regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 69,
1221–1229. doi: 10.1158/0008-5472.CAN-08-2516
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., et al. (2006).
Autophagy promotes tumor cell survival and restricts necrosis, inflammation,
and tumorigenesis. Cancer Cell 10, 51–64. doi: 10.1016/j.ccr.2006.06.001
Deveraux, Q. L., and Reed, J. C. (1999). IAP family proteins—suppressors of
apoptosis. Genes Dev. 13, 239–252. doi: 10.1101/gad.13.3.239
Druz, A., Chen, Y. C., Guha, R., Betenbaugh, M., Martin, S. E., and Shiloach, J.
(2013). Large-scale screening identifies a novel microRNA, miR-15a-3p, which
induces apoptosis in human cancer cell lines. RNA Biol. 10, 287–300. doi:
10.4161/rna.23339
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol.
35, 495–516. doi: 10.1080/01926230701320337
Ergun, S., and Oztuzcu, S. (2014). miR-221: a critical player in apoptosis as a target
of Caspase-3. Cancer Cell Microenviron. 1:e313. doi: 10.14800/ccm.313
Fasanaro, P., Greco, S., Lorenzi, M., Pescatori, M., Brioschi, M., Kulshreshtha, R.,
et al. (2009). An integrated approach for experimental target identification of
hypoxia-induced miR-210. J. Biol. Chem. 284, 35134–35143. doi: 10.1074/jbc.
m109.052779
Feliciano, A., Castellvi, J., Artero-Castro, A., Leal, J. A., Romagosa, C., Hernández-
Losa, J., et al. (2013). miR-125b acts as a tumor suppressor in breast
tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9.
PLoS ONE 8:e76247. doi: 10.1371/journal.pone.0076247
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M.,
et al. (2015). Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, 359–386. doi:
10.1002/ijc.29210
Ferracin, M., Bassi, C., Pedriali, M., Pagotto, S., D’Abundo, L., Zagatti, B., et al.
(2013). miR-125b targets erythropoietin and its receptor and their expression
correlates with metastatic potential and ERBB2/HER2 expression.Mol. Cancer
12:130. doi: 10.1186/1476-4598-12-130
Florea, A.-M., and Busselberg, D. (2013). Breast cancer and possible mechanisms
of therapy resistance. J. Local Glob. Health Sci. 2:9. doi: 10.5339/jlghs.
2013.2
Foekens, J. A., Sieuwerts, A. M., Smid, M., et al. (2008). Four miRNAs
associated with aggressiveness of lymph node-negative, estrogen receptor-
positive human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 13021–13026.
doi: 10.1073/pnas.0803304105
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow,M., Krogh, A., and Lund,
A. H. (2008). Programmed cell death 4 (PDCD4) is an important functional
target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283,
1026–1033. doi: 10.1074/jbc.M707224200
Frenzel, A., Grespi, F., Chmelewskij, W., and Villunger, A. (2009). Bcl2 family
proteins in carcinogenesis and the treatment of cancer. Apoptosis 14, 584–596.
doi: 10.1007/s10495-008-0300-z
Fulda, S., and Debatin, K.-M. (2006). Extrinsic versus intrinsic apoptosis pathways
in anticancer chemotherapy. Oncogene 25, 4798–4811. doi: 10.1038/sj.onc.
1209608
Gan, R., Yang, Y., Yang, X., Zhao, L., Lu, J., and Meng, Q. H. (2014).
Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to
tamoxifen through upregulation of TIMP3.Cancer Gene Ther. 21, 290–296. doi:
10.1038/cgt.2014.29
Gao, J., Li, L., Wu, M., Liu, M., Xie, X., Guo, J., et al. (2013). MiR-26a inhibits
proliferation and migration of breast cancer through repression of MCL-1.
PLoS ONE 8:e65138. doi: 10.1371/journal.pone.0065138
Godfrey, A. C., Xu, Z.,Weinberg, C. R., Getts, R. C.,Wade, P. A., DeRoo, L. A., et al.
(2013). Serum microRNA expression as an early marker for breast cancer risk
in prospectively collected samples from the Sister Study cohort. Breast Cancer
Res. 15, R42. doi: 10.1186/bcr3428
Goldberger, N., Walker, R. C., Kim, C. H., Winter, S., and Hunter, K. W.
(2013). Inherited variation in miR-290 expression suppresses breast cancer
Frontiers in Genetics | www.frontiersin.org 11 September 2016 | Volume 7 | Article 175
Sharma et al. ApoptomiRs of Breast Cancer: Basics to Clinics
progression by targeting the metastasis susceptibility gene Arid4b. Cancer Res.
73, 2671–2681. doi: 10.1158/0008-5472.CAN-12-3513
Gonzalez-Angulo, A. M., Morales-Vasquez, F., and Hortobagyi, G. N. (2007).
Overview of resistance to systemic therapy in patients with breast cancer. Adv.
Exp. Med. Biol. 608, 1–22. doi: 10.1007/978-0-387-74039-3_1
Guo, X., Wu, Y., and Hartley, R. S. (2009). MicroRNA-125a represses cell
growth by targeting HuR in breast cancer. RNA Biol. 6, 575–583. doi:
10.4161/rna.6.5.10079
Guttilla, I. K., and White, B. A. (2009). Coordinate regulation of FOXO1 by
miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 284,
23204–23216. doi: 10.1074/jbc.M109.031427
Hammond, S. M. (2006). microRNA detection comes of age. Nat. Methods 3,
12–13. doi: 10.1038/nmeth0106-12
He, T. Y. G., Yang, L., Yang, G., Chen, Y., and Zhang, X. (2015). The role of
miR-100 in regulating apoptosis of breast cancer cells. Sci. Rep. 5:11650. doi:
10.1038/srep11650
He, Y. J., Wu, J. Z., Ji, M. H., Ma, T., Qiao, E. Q., Ma, R., et al. (2013). miR-342
is associated with estrogen receptor-α expression and response to tamoxifen in
breast cancer. Exp. Ther. Med. 5, 813–818. doi: 10.3892/etm.2013.915
Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., et al. (2010).
Circulating microRNAs as novel minimally invasive biomarkers for breast
cancer. Ann. Surg. 251, 499–505. doi: 10.1097/SLA.0b013e3181cc939f
Hengartner, M. O. (2001). Apoptosis: corralling the corpses.Cell 104, 325–328. doi:
10.1016/S0092-8674(01)00219-7
Honma, N., Horii, R., Ito, Y., Saji, S., Younes, M., et al. (2015). Differences in
clinical importance of Bcl-2 in breast cancer according to hormone receptors
status or adjuvant endocrine therapy. BMCCancer.15:698. doi: 10.1186/s12885-
015-1686-y
Hu, Q. L., Jiang, Q. Y., Jin, X., Shen, J., Wang, K., Li, Y. B., et al. (2013).
Cationic microRNA-delivering nanovectors with bifunctional peptides for
efficient treatment of PANC-1 xenograft model. Biomaterials 34, 2265–2276.
doi: 10.1016/j.biomaterials.2012.12.016
Hu, W., Chan, C. S., Wu, R., Zhang, C., Sun, Y., Song, J. S., et al. (2010). Negative
regulation of tumor suppressor p53 by microRNA miR-504. Mol. Cell 38,
689–699. doi: 10.1016/j.molcel.2010.05.027
Hu, Y., Xu, K., and Yagüe, E. (2015). miR-218 targets survivin and regulates
resistance to chemotherapeutics in breast cancer. Breast Cancer Res. Treat. 151,
269–280. doi: 10.1007/s10549-015-3372-9
Hu, Y., Zhu, Q., and Tang, L. (2014). MiR-99a antitumor activity in human breast
cancer cells through targeting of mTOR expression. PLoS ONE 9:e92099. doi:
10.1371/journal.pone.0092099
Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009a). Systematic and
integrative analysis of large gene lists using DAVID bioinformatics resources.
Nature Protoc. 4, 44–57. doi: 10.1038/nprot.2008.211
Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009b). Bioinformatics
enrichment tools: paths toward the comprehensive functional analysis of large
gene lists. Nucleic Acids Res. 37, 1–13. doi: 10.1093/nar/gkn923
Iorio, M. V., Ferracin, M., Liu, C. G., et al. (2005). MicroRNA gene expression
deregulation in human breast cancer. Cancer Res. 65, 7065–7070. doi:
10.1158/0008-5472.CAN-05-1783
Janaki Ramaiah, M., Lavanya, A., Honarpisheh, M., Zarea, M., Bhadra, U., and
Bhadra, M. P. (2014). MiR-15/16 complex targets p70S6 kinase 1 and controls
cell proliferation in MDA-MB-231 breast cancer cells. Gene 552, 255–264. doi:
10.1016/j.gene.2014.09.052
Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M.,
Patel, K., et al. (2013). Treatment of HCV infection by targeting microRNA. N.
Engl. J. Med. 368, 1685–1694. doi: 10.1056/NEJMoa1209026
Jiang, S., Zhang, H.W., Lu,M. H., He, X. H., et al. (2010).MicroRNA-155 functions
as an OncomiR in breast cancer by targeting the suppressor of cytokine
signaling 1 gene. Cancer Res. 70, 3119–3127. doi: 10.1158/0008-5472.CAN-
09-4250
Joshi-Tope, G., Gillespie, M., Vastrik, I., D’Eustachio, P., Schmidt, E., et al. (2005).
Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 33,
D428–D432. doi: 10.1093/nar/gki072
Jung, E. J., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., et al. (2012). Plasma
microRNA 210 levels correlate with sensitivity to trastuzumab and tumor
presence in breast cancer patients. Cancer 118, 2603–2614. doi: 10.1002/cncr.
26565
Kasibhatla, S., and Tseng, B. (2003). Why target apoptosis in cancer treatment?
Mol. Cancer Ther. 2, 573–580.
Kato, M., Paranjape, T., Müller, R. U., Nallur, S., Gillespie, E., Keane, K., et al.
(2009). Themir-34microRNA is required for the DNA damage response in vivo
in C. elegans and in vitro in human breast cancer cells.Oncogene 28, 2419–2424.
doi: 10.1038/onc.2009.106
Kodahl, A. R., Lyng, M. B., Binder, H., Cold, S., Gravgaard, K., Knoop, A. S.,
et al. (2014). Novel circulating microRNA signature as a potential non-invasive
multi-marker test in ER-positive early-stage breast cancer: a case control study.
Mol. Oncol. 8, 874–883. doi: 10.1016/j.molonc.2014.03.002
Kong, W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D., et al.
(2010). MicroRNA-155 regulates cell survival, growth, and chemosensitivity
by targeting FOXO3a in breast cancer. J. Biol. Chem. 285, 17869–17879. doi:
10.1074/jbc.M110.101055
Kong,W., He, L., Richards, E. J., Challa, S., Xu, C. X., Permuth-Wey, J., et al. (2014).
Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL
and is associated with poor prognosis and triple-negative breast cancer.
Oncogene 33, 679–689. doi: 10.1038/onc.2012.636
Kong, W., Yang, H., He, L., Zhao, J. J., Coppola, D., et al. (2008). MicroRNA-155 is
regulated by the transforming growth factor β/smad pathway and contributes
to epithelial cell plasticity by targeting RhoA.Mol. Cell Biol. 28, 6773–6784. doi:
10.1128/MCB.00941-08
Körner, C., Keklikoglou, I., Bender, C., Wörner, A., Münstermann, E., and
Wiemann, S. (2013). MicroRNA-31 sensitizes human breast cells to apoptosis
by direct targeting of protein kinase C epsilon (PKCepsilon). J. Biol. Chem. 288,
8750–8761. doi: 10.1074/jbc.M112.414128
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., et al. (2008). Involvement
of microRNA-451 in resistance of the MCF7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7, 2152–2159. doi:
10.1158/1535-7163.MCT-08-0021
Krutovskikh, V. A., and Herceg, Z. (2010). Oncogenic microRNAs (OncomiRs)
as a new class of cancer biomarkers. Bioessays 32, 894–904. doi:
10.1002/bies.201000040
Lee, J. A., Lee, H. Y., Lee, E. S., Kim, I., and Bae, J. W. (2011). Prognostic
implications of microRNA-21 overexpression in invasive ductal carcinomas of
the breast. J. Breast Cancer14:269. doi: 10.4048/jbc.2011.14.4.269
Leivonen, S. K., Sahlberg, K. K., Mäkelä, R., Due, E. U., et al. (2014). High-
throughput screens identify microRNAs essential for HER2 positive breast
cancer cell growth.Mol. Oncol. 8, 93–104. doi: 10.1016/j.molonc.2013.10.001
Li, B., Lu, Y., Wang, H., Han, X., Mao, J., Li, J., et al. (2016). miR-221/222 enhance
the tumorigenicity of human breast cancer stem cells via modulation of
PTEN/Akt pathway. Biomed. Pharmacother. 79, 93–101. doi: 10.1016/j.biopha.
2016.01.045
Li, J. H., Liu, S., Zhou, H., Qu, L. H., and Yang, J. H. (2014). starBase
v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction
networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92–D97. doi:
10.1093/nar/gkt1248
Li, L., Yuan, L., Luo, J., Gao, J., Guo, J., and Xie, X. (2013). MiR-34a inhibits
proliferation and migration of breast cancer through down-regulation of Bcl-2
and SIRT1. Clin. Exp. Med. 13, 109–117. doi: 10.1007/s10238-012-0186-5
Li, M., Ma, X., Li, M., Zhang, B., et al. (2014). Prognostic role of microRNA-210
in various carcinomas: a syst ematic review and meta-analysis. Dis. Markers.
2014:106197. doi: 10.1155/2014/106197
Li, W., Zang, W., Liu, P., Wang, Y., Du, Y., Chen, X., et al. (2014). MicroRNA-124
inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer.
Tumour Biol. 35, 10897–10904. doi: 10.1007/s13277-014-2402-2
Li, X. J., Ji, M. H., Zhong, S. L., Zha, Q. B., et al. (2012). MicroRNA-34a modulates
chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.Arch.
Med. Res. 43, 514–521. doi: 10.1016/j.arcmed.2012.09.007
Lipponen, P. (1999). Apoptosis in breast cancer: relationship with
other pathological parameters. Endocr. Relat. Cancer 6, 13–16. doi:
10.1677/erc.0.0060013
Lipponen, P., Aaltomaa, S., Kosma, V.-M., and Syrjänen, K. (1994). Apoptosis in
breast cancer as related to histopathological characteristics and prognosis. Eur.
J. Cancer 30A, 2068–2073. doi: 10.1016/0959-8049(94)00342-3
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al. (2011).
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by
directly repressing CD44. Nat. Med. 17, 211–215. doi: 10.1038/nm.2284
Frontiers in Genetics | www.frontiersin.org 12 September 2016 | Volume 7 | Article 175
Sharma et al. ApoptomiRs of Breast Cancer: Basics to Clinics
Liu, H., Wang, Y., Li, X., Zhang, Y. J., Li, J., Zheng, Y. Q., et al. (2013).
Expression and regulatory function of miRNA-182 in triple-negative breast
cancer cells through its targeting of profilin 1. Tumour Biol. 34, 1713–1722. doi:
10.1007/s13277-013-0708-0
Liu, R., Liu, C., Chen, D., Yang, W. H., Liu, X., Liu, C. G., et al. (2015). FOXP3
controls an miR-146/NF-κB negative feedback loop that inhibits apoptosis in
breast cancer cells. Cancer Res. 75, 1703–1713. doi: 10.1158/0008-5472.CAN-
14-2108
Liu, X. X., Li, X. J., Zhang, B., Liang, Y. J., Zhou, C. X., Cao, D. X.,
et al. (2011). MicroRNA-26b is underexpressed in human breast cancer and
induces cell apoptosis by targeting SLC7A11. FEBS Lett. 585, 1363–1367. doi:
10.1016/j.febslet.2011.04.018
Lu, K., Wang, J., Song, Y., Zhao, S., Liu, H., et al. (2015). miRNA-24-3p promotes
cell proliferation and inhibits apoptosis in human breast cancer by targeting
p27Kip1. Oncol. Rep. 34, 995–1002. doi: 10.3892/or.2015.4025
Luo, E. C., Chang, Y. C., Sher, Y. P., Huang, W. Y., Chuang, L. L., et al. (2014).
MicroRNA-769-3p down-regulates NDRG1 and enhances apoptosis in MCF7
cells during reoxygenation. Sci. Rep. 4:e5908. doi: 10.1038/srep05908
Luo, Q., Li, X., Li, J., Kong, X., Zhang, J., Chen, L., et al. (2013). MiR-15a is
underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
Int. J. Oncol. 43, 1212–1218. doi: 10.3892/ijo.2013.2034
Luthra, R., Singh, R. R., Luthra, M. G., Li, Y. X., Hannah, C., Romans, A.
M., et al. (2008). MicroRNA-196a targets annexin A1: a microRNA-mediated
mechanism of annexin A1 downregulation in cancers.Oncogene 27, 6667–6678.
doi: 10.1038/onc.2008.256
Lyng, M. B., Laenkholm, A. V., Sokilde, R., et al. (2012). Global microRNA
expression profiling of high-risk ER+ breast cancers from patients receiving
adjuvant tamoxifen mono-therapy: a DBCG study. PLoS ONE 7:e36170. doi:
10.1371/journal.pone.0036170
Mackiewicz, M., Huppi, K., Pitt, J. J., Dorsey, T. H., Ambs, S., and Caplen, N.
J. (2011). Identification of the receptor tyrosine kinase AXL in breast cancer
as a target for the human miR-34a microRNA. Breast Cancer Res. Treat. 130,
663–679. doi: 10.1007/s10549-011-1690-0
Maillot, G., Lacroix-Triki, M., Pierredon, S., et al. (2009). Widespread estrogen-
dependent repression of micrornas involved in breast tumor cell growth.
Cancer Res. 69, 8332–8340. doi: 10.1158/0008-5472.CAN-09-2206
Mattick, J. S., and Makunin, I. V. (2006). Non-coding RNA. Hum. Mol. Genet. 15,
R17–R29. doi: 10.1093/hmg/ddl046
Megha, T., Ferrari, F., Benvenuto, A., Bellan, C., Lalinga, A. V., Lazzi, S., et al.
(2002). p53 mutation in breast cancer. Correlation with cell kinetics and cell of
origin. J. Clin. Pathol. 55, 461–466. doi: 10.1136/jcp.55.6.461
Mei, M., Ren, Y., Zhou, X., Yuan, X. B., Han, L., Wang, G. X., et al. (2010).
Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast
carcinoma cells. Technol. Cancer Res. Treat. 9, 77–86. doi: 10.1177/153303
461000900109
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., et al. (2008).
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting
p27Kip1. J. Biol. Chem. 283, 29897–29903. doi: 10.1074/jbc.M804612200
Molloy, N. H., Read, D. E., and Gorman, A. M. (2011). Nerve growth factor
in cancer cell death and survival. Cancers 3, 510–530. doi: 10.3390/cancers
3010510
Mosca, E., Alfieri, R., Merelli, I., Viti, F., Calabria, A., and Milanesi, L. (2010). A
multilevel data integration resource for breast cancer study. BMC Syst. Biol.
4:76. doi: 10.1186/1752-0509-4-76
Nagpal, N., Ahmad, H. M., Molparia, B., and Kulshreshtha, R. (2013). MicroRNA-
191, an estrogen-responsive microRNA, functions as an oncogenic regulator in
human breast cancer.Carcinogenesis 34, 1889–1899. doi: 10.1093/carcin/bgt107
Nana-Sinkam, S. P., and Croce, C. M. (2013). Clinical applications for
microRNAs in cancer. Clin. Pharmacol. Ther. 93, 98–104. doi: 10.1038/clpt.
2012.192
Ng, E. K., Li, R., Shin, V. Y., Jin, H. C., Leung, C. P., Ma, E. S., et al. (2013).
CirculatingmicroRNAs as specific biomarkers for breast cancer detection. PLoS
ONE 8:e53141. doi: 10.1371/journal.pone.0053141
Okamura, S., Arakawa, H., Tanaka, T., Nakanishi, H., et al. (2001). p53DINP1, a
p53-inducible gene, regulates p53-dependent apoptosis.Mol. Cell 8, 85–94. doi:
10.1016/S1097-2765(01)00284-2
Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer.N. Engl. J.Med.
339, 1609–1618. doi: 10.1056/NEJM199811263392207
Park, E. Y., Chang, E., Lee, E. J., Lee, H. W., Kang, H. G., Chun, K. H., et al.
(2014). Targeting ofmiR34a-NOTCH1 axis reduced breast cancer stemness and
chemoresistance. Cancer Res. 74, 7573–7582. doi: 10.1158/0008-5472.CAN-
14-1140
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I.,
and Kovalchuk, O. (2010). Alterations of microRNAs and their targets are
associated with acquired resistance of MCF7 breast cancer cells to cisplatin. Int.
J. Cancer 127, 1785–1794. doi: 10.1002/ijc.25191
Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor
progression and metastasis. Nat. Med. 11, 1423–1437. doi: 10.1038/nm.3394
Rajabi, H., Jin, C., Ahmad, R., McClary, A. C., Joshi, M. D., and Kufe, D., (2010).
Mucin 1 oncoprotein expression is suppressed by themiR-125b oncomir.Genes
Cancer 1, 62–68. doi: 10.1177/1947601909357933
Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., et al. (2011). MicroRNA-221/222
confers breast cancer fulvestrant resistance by regulating multiple signaling
pathways. Oncogene 30, 1082–1097. doi: 10.1038/onc.2010.487
Rivas, M. A., Venturutti, L., Huang, Y. W., Schillaci, R., Huang, T. H., and Elizalde,
P. V. (2012). Downregulation of the tumor-suppressor miR-16 via progestin-
mediated oncogenic signaling contributes to breast cancer development. Breast
Cancer Res. 14, R77. doi: 10.1186/bcr3187
Ru, P., Steele, R., Hsueh, E. C., and Ray, R. B. (2011). Anti-miR-203
upregulates SOCS3 expression in breast cancer cells and enhances cisplatin
chemosensitivity. Genes Cancer 2, 720–727. doi: 10.1177/1947601911
425832
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., et al. (2009). p53
represses c-Myc through induction of the tumor suppressor miR-145. Proc.
Natl. Acad. Sci. U.S.A. 106, 3207–3212. doi: 10.1073/pnas.0808042106
Schooneveld, E. V., Wildiers, H., Vergote, I., Vermeulen, P. B., Dirix, L. Y., and
Van Laere, S. J. (2015). Dysregulation of microRNAs in breast cancer and their
potential role as prognostic and predictive biomarkers in patient management.
Breast Cancer Res. 17, 21. doi: 10.1186/s13058-015-0526-y
Shen, L., Li, J., Xu, L., Ma, J., Li, H., Xiao, X., et al. (2012). miR-497 induces
apoptosis of breast cancer cells by targeting Bcl-w. Exp. Ther. Med. 3, 475–480.
doi: 10.3892/etm.2011.428
Shi, Y., Luo, X., Li, P., Tan, J., Wang, X., et al. (2015). miR-7-5p suppresses cell
proliferation and induces apoptosis of breast cancer cells mainly by targeting
REGγ. Cancer Lett. 358, 27–36. doi: 10.1016/j.canlet.2014.12.014
Si, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., and Mo, Y.-Y. (2007). miR-
21-mediated tumor growth. Oncogene 26, 2799–2803. doi: 10.1038/sj.onc.
1210083
Silvestrini, R., Benini, E., Veneroni, S., Daidone, M. G., Tomasic, G., et al.
(1996). p53 and bcl-2 expression correlates with clinical outcome in a series
of node-positive breast cancer patients. J. Clin. Oncol. 14, 1604–1610.
Song, B., Wang, C., Liu, J., Wang, X., Lv, L., Wei, L., et al. (2010). MicroRNA-
21 regulates breast cancer invasion partly by targeting tissue inhibitor of
metalloproteinase 3 expression. J. Exp. Clin. Cancer Res. 29:29. doi: 10.1186/
1756-9966-29-29
Song, C. G., Wu, X. Y., Wang, C., Fu, F. M., and Shao, Z. M. (2012). Correlation
of miR-155 on formalin-fixed paraffin embedded tissues with invasiveness and
prognosis of breast cancer. Zhonghua Wai Ke Za Zhi 50, 1011–1014. doi:
10.3760/cma.j.issn.0529-5815.2012.11.012
Srivastava, N., Manvati, S., Srivastava, A., Pal, R., Kalaiarasan, P., Chattopadhyay,
S., et al. (2011). miR-24-2 controls H2AFX expression regardless of gene copy
number alteration and induces apoptosis by targeting antiapoptotic gene BCL-
2: a potential for therapeutic intervention. Breast Cancer Res. 13, R39. doi:
10.1186/bcr2861
Stankevicins, L., Almeida da Silva, A. P., Ventura Dos Passos, F., Dos Santos
Ferreira, E., Menks Ribeiro, M. C. G., David, M., et al. (2013). MiR-34a is up-
regulated in response to low dose, low energy X-ray induced DNA damage in
breast cells. Radiat. Oncol. 8:231. doi: 10.1186/1748-717X-8-231
Sun, L. L., Wang, J., Zhao, Z. J., Liu, N., Wang, A. L., et al. (2014). Suppressive role
of miR-502-5p in breast cancer via downregulation of TRAF2. Oncol. Rep. 31,
2085–2092. doi: 10.3892/or.2014.3105
Thorsen, S. B., Obad, S., Jensen, N. F., Stenvang, J., and Kauppinen, S. (2012).
The therapeutic potential of microRNAs in cancer. Cancer J. 18, 275–284. doi:
10.1097/PPO.0b013e318258b5d6
Vakkala, M., Lahteenmaki, K., Raunio, H., Paakko, P., and Soini, Y. (1999).
Apoptosis during breast carcinoma progression. Clin. Cancer Res. 5, 319–324.
Frontiers in Genetics | www.frontiersin.org 13 September 2016 | Volume 7 | Article 175
Sharma et al. ApoptomiRs of Breast Cancer: Basics to Clinics
Valabrega, G., Montemurro, F., and Aglietta, M. (2007). Trastuzumab: mechanism
of action, resistance and future perspectives in HER2-overexpressing breast
cancer. Ann. Oncol. 18, 977–984. doi: 10.1093/annonc/mdl475
Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., et al.
(2006). A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257–2261. doi: 10.1073/
pnas.0510565103
Volinia, S., Galasso, M., Sana, M. E., Wise, T. F., et al. (2012). Breast cancer
signatures for invasiveness and prognosis defined by deep sequencing of
microRNA. Proc. Natl. Acad. Sci. U.S.A. 109, 1–6. doi: 10.1073/pnas.120
0010109
Von Mering, C., Jensen, L. J., Snel, B., Hooper, S. D., Krupp, M., et al.
(2005). STRING: known and predicted protein–protein associations integrated
and transferred across organisms. Nucleic Acids Res. 33, D433–D437. doi:
10.1093/nar/gki005
Wang, F., Hou, J., Jin, W., Li, J., Yue, Y., Jin, H., et al. (2014). Increased circulating
microRNA-155 as a potential biomarker for breast cancer screening: a meta-
analysis.Molecules 19, 6282–6293. doi: 10.3390/molecules19056282
Wang, J., Zhao, J., Shi, M., Ding, Y., et al. (2014). Elevated expression of miR-210
predicts poor survival of cancer patients: a systematic review andmeta-analysis.
PLoS ONE 9:e89223. doi: 10.1371/journal.pone.0089223
Wang, L., Gao, W., Hu, F., Xu, Z., and Wang, F. (2014). MicroRNA-874 inhibits
cell proliferation and induces apoptosis in human breast cancer by targeting
CDK9. FEBS Lett. 588, 4527–4535. doi: 10.1016/j.febslet.2014.09.035
Wang, S., Bian, C., Yang, Z., Bo, Y., Li, J., Zeng, L., et al. (2009). miR-145 inhibits
breast cancer cell growth through RTKN. Int. J. Oncol. 34, 1461–1466. doi:
10.3892/ijo_00000275
Wang, S., Li, H., Wang, J., andWang, D. (2013). Expression of microRNA-497 and
its prognostic significance in human breast cancer. Diagn Pathol. 8:172. doi:
10.1186/1746-1596-8-172
Wang, Z. X., Lu, B. B., Wang, H., Cheng, Z. X., and Yin, Y. M. (2011).
MicroRNA-21modulates chemosensitivity of breast cancer cells to doxorubicin
by targeting PTEN. Arch. Med. Res. 42, 281–290. doi: 10.1016/j.arcmed.
2011.06.008
Wei, Y., Lai, X., Yu, S., Chen, S., Ma, Y., Zhang, Y., et al. (2014). Exosomal miR-
221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer
cells. Breast Cancer Res. Treat. 147, 423–431. doi: 10.1007/s10549-014-3037-0
Xiao, X., Huang, X., Ye, F., Chen, B., Song, C., Wen, J., et al. (2016). The miR-34a-
LDHA axis regulates glucose metabolism and tumor growth in breast cancer.
Sci. Rep. 6:21735. doi: 10.1038/srep21735
Yamakuchi, M., Ferlito, M., and Lowenstein, C. J. (2008). miR-34a repression of
SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13421–13426. doi:
10.1073/pnas.0801613105
Yan, L. X., Wu, Q. N., Zhang, Y., Li, Y. Y., Liao, D. Z., et al. (2011). Knockdown
of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro
migration and in vivo tumor growth. Breast Cancer Res. 13:e2803. doi:
10.1186/bcr2803
Yang, S., Li, Y., Gao, J., Zhang, T., Li, S., Luo, A., et al. (2013). MicroRNA-34
suppresses breast cancer invasion and metastasis by directly targeting Fra-1.
Oncogene 32, 4294–4303. doi: 10.1038/onc.2012.432
Yang, Y., Chaerkady, R., Beer, M. A., Mendell, J. T., and Pandey, A.
(2009). Identification of miR-21 targets in breast cancer cells using a
quantitative proteomic approach. Proteomics 9, 1374–1384. doi: 10.1002/pmic.
200800551
Ye, X., Bai, W., Zhu, H., Zhang, X., Chen, Y., Wang, L., et al. (2014). MiR-
221 promotes trastuzumab-resistance and metastasis in HER2-positive breast
cancers by targeting PTEN. BMB Rep. 47, 268–273. doi: 10.5483/BMBRep.
2014.47.5.165
Yu, Z., Xu, Z., Disante, G.,Wright, J., et al. (2014). miR-17/20 sensitization of breast
cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget 5,
1083–1090. doi: 10.18632/oncotarget.1804
Zhang, B., Liu, X. X., He, J. R., Zhou, C. X., Guo, M., He, M., et al.
(2011). Pathologically decreased miR-26a antagonizes apoptosis and facilitates
carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis
32, 2–9. doi: 10.1093/carcin/bgq209
Zhang, C., Liu, J., Tan, C., Yue, X., Zhao, Y., Peng, J., et al. (2016). microRNA-1827
represses MDM2 to to positively regulate tumor suppressor p53 and suppress
tumorigenesis. Oncotarget. 7, 8783–8796. doi: 10.18632/oncotarget.7088
Zhang, C., Zhang, J., Zhang, A., Wang, Y., Han, L., et al. (2010). PUMA is a novel
target of miR-221/222 in human epithelial cancers. Int. J. Oncol. 37, 1621–1626.
doi: 10.3892/ijo_00000816
Zhang, C. M., Zhao, J., and Deng, H. (2013). MiR-155 promotes proliferation of
human breast cancer MCF7 cells through targeting tumor protein 53-induced
nuclear protein 1. J. Biomed. Sci. 20:79. doi: 10.1186/1423-0127-20-79
Zhang, G., Liu, Z., Cui, G., Wang, X., and Yang, Z. (2014). MicroRNA-486-5p
targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour
Biol. 35, 11137–11145. doi: 10.1007/s13277-014-2412-0
Zhao, G., Guo, J., Li, D., Jia, C., Yin, W., Sun, R., et al. (2013). MicroRNA-34a
suppresses cell proliferation by targeting LMTK3 in human breast cancerMCF7
cell line. DNA Cell Biol. 32, 699–707. doi: 10.1089/dna.2013.2130
Zhao, J. J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., et al. (2008). MicroRNA-
221/222 negatively regulates estrogen receptor alpha and is associated with
tamoxifen resistance in breast cancer. J. Biol. Chem. 283, 31079–31086. doi:
10.1074/jbc.M806041200
Zhou, E., Hui, N., Shu, M., Wu, B., and Zhou, J. (2015). Systematic analysis of the
p53-related microRNAs in breast cancer revealing their essential roles in the
cell cycle. Oncol Lett. 10, 3488–3494. doi: 10.3892/ol.2015.3751
Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., et al. (2010). MicroRNA-125b
confers the resistance of breast cancer cells to paclitaxel through suppression
of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem. 285,
21496–21507. doi: 10.1074/jbc.M109.083337
Zhu, S., Si, M. L., Wu, H., and Mo, Y. Y. (2007). MicroRNA-21 targets the tumor
suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328–14336. doi:
10.1074/jbc.M611393200
Zhu, Y., Wu, J., Li, S., Ma, R., et al. (2013). The function role of miR-181a in
chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer
cells. Cell Physiol. Biochem. 32, 1225–1237. doi: 10.1159/000354521
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer KT and handling editor declared their shared affiliation, and
the handling editor states that the process nevertheless met the standards of a fair
and objective review.
Copyright © 2016 Sharma, Patnaik, Aronov and Kulshreshtha. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 14 September 2016 | Volume 7 | Article 175
